This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | MicrobiomeTrials

NCT03016377

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2012-03-22Est. Completion: 2025-09-12

Enrollment target: 15 participants

Locations

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

B-AllAcute Lymphoblastic Leukemia

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat peopl…

Los Angeles, United StatesEst. completion Dec 31, 2026

Acute Lymphoblastic Leukemia

This is a prospective specimen collection study evaluating the feasibility of using the ChromoSeq® assay for upfront cla…

St Louis, United StatesEst. completion Jul 15, 2028

Acute Lymphoblastic LeukemiaB-All

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy invol…

Bethesda, United StatesEst. completion Jan 31, 2030

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.